Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors

February 21, 2024 updated by: Fujian Maternity and Child Health Hospital
The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy biopsy pathology results. At the same time, paraffin tissue specimens (remaining specimens after pathological diagnosis) from 100 cases of cervical neuroendocrine tumors from multiple centers across the country were collected to establish a cervical neuroendocrine tumor data follow-up database. Protein concentration and omics analysis were performed on the data results, to evaluate the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins, and to preliminarily explore its clinical application value.

Study Overview

Status

Recruiting

Conditions

Detailed Description

1. The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were used for prognostic analysis.

(1) The diagnosis and treatment information of cervical neuroendocrine carcinoma in multiple hospitals was collected, including clinical and medical data such as age, preoperative HPV genotyping, preoperative biopsy pathological results, postoperative histopathological results, FIGO staging, prognosis and survival information, and follow-up of patients.

2. Protein and other omics analysis was performed on paraffin tissues of 100 cases of cervical neuroendocrine tumors Paraffin samples collected from 100 cases of cervical neuroendocrine tumors were identified, processed and segmtioned, and protein concentration and proteome were determined to establish the molecular characteristics and prognostic targets of cervical neuroendocrine tumors.

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Fujian
      • Fuzhou, Fujian, China, 350001
        • Recruiting
        • Fujian Maternity and Child Health Hospital
        • Contact:
      • Fuzhou, Fujian, China
        • Recruiting
        • Fujian Provincial Hospital
        • Contact:
          • Dongjie Chen
      • Ningde, Fujian, China
        • Recruiting
        • Ningde Mindong Hospital
        • Contact:
          • Fang Xie
      • Putian, Fujian, China
        • Recruiting
        • Putian City first Hospital
        • Contact:
          • Yi Chen
      • Quanzhou, Fujian, China
        • Recruiting
        • The Second Affiliated Hospital of Fujian Medical University
        • Contact:
          • Luhong Li
      • Zhangzhou, Fujian, China, 363000
        • Recruiting
        • Zhangzhou Affiliated Hospital of Fujian Medical University
        • Contact:
          • Feifeng Shi, M.D
    • Hubei
      • Wuhan, Hubei, China
        • Recruiting
        • Maternal and Child Health Hospital of Hubei Province
        • Contact:
          • Hongning Cai, M.D
          • Phone Number: +8615926224867
    • Hunan
      • Changsha, Hunan, China
        • Recruiting
        • Xiangya Hospital, Central South University
        • Contact:
          • Yu Zhang
    • Jiangxi
      • Nanchang, Jiangxi, China
        • Recruiting
        • Jiangxi Maternal and Child Health Hospital
        • Contact:
          • Ling Li

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All 300 patients were diagnosed with cervical neuroendocrine carcinoma by histopathology

Description

Inclusion Criteria:

  1. Patients diagnosed with cervical neuroendocrine carcinoma by histopathology
  2. Clinical data were complete

Exclusion Criteria:

  1. Patients who are not being treated in our hospital
  2. Patients with lack of follow-up data, unable to obtain survival information
  3. Patients call to refuse to participate in this project
  4. The quality of paraffin specimens can not meet the requirements of proteome concentration determination

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
mortality rate
Time Frame: Among patients with cervical neuroendocrine carcinoma, the mortality rate within 3 years following surgery
3-year mortality rate for cervical neuroendocrine carcinoma
Among patients with cervical neuroendocrine carcinoma, the mortality rate within 3 years following surgery
Disease-free survival
Time Frame: Among patients with cervical neuroendocrine carcinoma, the disease-free survival within 3 years following surgery
3-year disease-free survival for cervical neuroendocrine carcinoma
Among patients with cervical neuroendocrine carcinoma, the disease-free survival within 3 years following surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fujian Maternity and Child Health Hospital

Investigators

  • Study Chair: Pengming Sun, PhD, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2024

Primary Completion (Estimated)

June 30, 2024

Study Completion (Estimated)

June 30, 2024

Study Registration Dates

First Submitted

February 7, 2024

First Submitted That Met QC Criteria

February 21, 2024

First Posted (Actual)

February 23, 2024

Study Record Updates

Last Update Posted (Actual)

February 23, 2024

Last Update Submitted That Met QC Criteria

February 21, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NECC2401

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe